Loading asset research
Prelude Therapeutics Incorporated Common Stock
PRLDNasdaq · USD · StocksQuote as of · Exchange session not verified$3.87
-10.21%
Today
PRLD
Loading 1D prices…
Market cap
$317.8M
Volume
1M
52w high
$6.8352w low
$1.15Company profile
Prelude Therapeutics Incorporated Common Stock
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Wilmington, DE, United States
Employees
79
Fiscal year end
1231
CIK
1678660
Session & valuation
Open$4.31
Previous close$4.31
Day high$4.32
Day low$3.86
30-day avg. volume572.7K
Outstanding shares79.8M
Diluted EPS-$1.29
Latest annual period
P/E (trailing)-3.00
P/E (forward)-5.18
Price / book3.07
Beta0.96
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| EVMNEvommune Inc. Common Stock | $319.4M | $13M | -529.77% | -$11.22 | -4.73% | Buy |
| BBOTBridgeBio Oncology Therapeutics Inc. Common Stock | $319.9M | $0.00 | — | -$4.30 | -5.29% | Buy |
| ABEOAbeona Therapeutics Inc. Common Stock | $310.5M | $5.8M | -1223.08% | $1.01 | -2.17% | Buy |
| BIOABioAge Labs Inc. Common Stock | $330.9M | $9M | -896.11% | -$2.24 | -8.49% | Buy |
| VNDAVanda Pharmaceuticals Inc. Common Stock | $301.1M | $216.1M | -102.03% | -$3.74 | -0.00% | Buy |